Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Phase 2TerminatedNCT00070291

Eastern Cooperative Oncology Group4 enrolled

Overview

RATIONALE: Cyclosporine may help the immune system slow the growth of angioimmunoblastic T-cell lymphoma. PURPOSE: This phase II trial is studying how well cyclosporine works in treating patients with recurrent or refractory angioimmunoblastic T-cell lymphoma.

OBJECTIVES: Primary * Determine the response rate (complete and partial) in patients with recurrent or refractory angioimmunoblastic T-cell lymphoma treated with cyclosporine. Secondary * Determine the disease-free, progression-free, and overall survival of patients treated with this drug. * Determine the toxicity of this drug in these patients. OUTLINE: Patients receive oral cyclosporine twice daily for up to 36 weeks in the absence of unacceptable toxicity or disease progression during weeks 1-6. Patients experiencing disease progression during weeks 7-36, receive an additional 36 weeks of therapy. Patients are followed every 3 months for 2 years and then every 6 months for 1 year. PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study within 2.5 years.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma

Interventions

cyclosporineDRUG

Cyclosporine doses will be based on actual body weight unless actual body weight is \> 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on histologic examination. * At least one objective measurable or evaluable disease parameter. * Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid treatment. Patients may not receive concurrent chemotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Adequate renal function as indicated by creatinine \<= 1.5 the upper limit of normal (ULN). * Adequate liver function as indicated by alkaline phosphatase, Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) \<= 2x the upper limit of normal. * Total bilirubin \<= 2x the upper limit of normal. * Age 18 or older. Exclusion Criteria: * Prior cyclosporine or Tacrolimus (FK506). * Prior allogeneic transplant. * Evidence of active infection. * Congestive heart failure, kidney failure, liver failure, or other severe co-morbidities. * Evidence of active neurological impairment. * Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL (polyoxyethylated oil). * History of other malignancies (other than cured carcinomas in situ of the cervix or basal cell carcinoma of the skin). * pregnant or breastfeeding women. * Human immunodeficiency virus (HIV) positive.

Locations (23)

Stanford Cancer Center

Outcomes

Primary Outcomes

Response Rate (Complete and Partial Response)

Response was assessed based upon the criteria from the International Workshop to Standardize Criteria for Non-Hodgkin's Lymphoma. Response included complete response and partial response. Complete response was defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related B-symptoms if present prior to therapy, as well as normalization of those biochemical abnormalities definitely attributed to NHL. All lymph nodes and nodal masses must have regressed to normal size. Partial response was defined as a decrease of \> 50% in the SPD (sum of the products of the diameters) of the six largest (or less) dominant nodes or nodal masses, no increase in the size of the liver or the spleen, and no new sites of disease.

Time frame: Assessed at weeks 6, 12, 24 and 36 from onset of treatment, and then at 1 year, 18 months, 2 years and 3 years from registration during follow-up.

Secondary Outcomes

Overall Survival

Overall survival was defined as time from randomization to death from any cause.

Time frame: Assessed every 3 months for 2 years, then every 6 months for 1 year.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.